Pamela J Goodwin1, Wendy R Parulekar2, Karen A Gelmon2, Lois E Shepherd2, Jennifer A Ligibel2, Dawn L Hershman2, Priya Rastogi2, Ingrid A Mayer2, Timothy J Hobday2, Julie Lemieux2, Alastair M Thompson2, Kathleen I Pritchard2, Timothy J Whelan2, Som D Mukherjee2, Haji I Chalchal2, Conrad D Oja2, Katia S Tonkin2, Vanessa Bernstein2, Bingshu E Chen2, Vuk Stambolic2. 1. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada (PJG); NCIC Clinical Trials Group, Cancer Research Institute, Queen's University, Kingston, Ontario, Canada (WRP, LES, BEC); NCIC Clinical Trials Group, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada (KAG); Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (JAL); Columbia University Medical Center, New York, NY (DLH); National Surgical Adjuvant Breast and Bowel Project, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA (PR); Vanderbilt-Ingram Medical Center, Vanderbilt University Medical Center, Nashville, TN (IAM); Mayo Clinic College of Medicine, Rochester, MN (TJH); Centre de recherche du CHU de Québec, Unité de recherche en santé des populations Hôpital du Saint-Sacrement, Quebec, Quebec, Canada (JL); National Cancer Research Institute Breast Clinical Studies Group, London, UK (AMT); Sunnybrook Odette Cancer Center, University of Toronto, Toronto, Ontario, Canada (KIP); Juravinski Cancer Center at Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada (TJW, SDM); Allan Blair Cancer Centre, Regina, Saskatchewan, Canada (HIC); British Columbia Cancer Agency, Fraser Valley Center, Surrey, British Columbia, Canada (CDO); University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada (KST); British Columbia Cancer Agency - Vancouver Island Center, University of British Columbia, British Columbia, Canada (VB); Ontario Cancer Institute, University Health Network, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada (VS). pgoodwin@mtsinai.on.ca. 2. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada (PJG); NCIC Clinical Trials Group, Cancer Research Institute, Queen's University, Kingston, Ontario, Canada (WRP, LES, BEC); NCIC Clinical Trials Group, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada (KAG); Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (JAL); Columbia University Medical Center, New York, NY (DLH); National Surgical Adjuvant Breast and Bowel Project, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA (PR); Vanderbilt-Ingram Medical Center, Vanderbilt University Medical Center, Nashville, TN (IAM); Mayo Clinic College of Medicine, Rochester, MN (TJH); Centre de recherche du CHU de Québec, Unité de recherche en santé des populations Hôpital du Saint-Sacrement, Quebec, Quebec, Canada (JL); National Cancer Research Institute Breast Clinical Studies Group, London, UK (AMT); Sunnybrook Odette Cancer Center, University of Toronto, Toronto, Ontario, Canada (KIP); Juravinski Cancer Center at Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada (TJW, SDM); Allan Blair Cancer Centre, Regina, Saskatchewan, Canada (HIC); British Columbia Cancer Agency, Fraser Valley Center, Surrey, British Columbia, Canada (CDO); University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada (KST); British Columbia Cancer Agency - Vancouver Island Center, University of British Columbia, British Columbia, Canada (VB); Ontario Cancer Institute, University Health Network, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada (VS).
Abstract
BACKGROUND:Metformin may improve metabolic factors (insulin, glucose, leptin, highly sensitive C-reactive protein [hs-CRP]) associated with poor breast cancer outcomes. The NCIC Clinical Trials Group (NCIC CTG) MA.32 investigates effects of metformin vs placebo on invasive disease-free survival and other outcomes in early breast cancer. Maintaining blinding of investigators to outcomes, we conducted a planned, Data Safety Monitoring Committee-approved, analysis of the effect of metformin vs placebo on weight and metabolic factors at six months, including examination of interactions with baseline body mass index (BMI) and insulin, in the first 492 patients with paired blood samples. METHODS:Eligible nondiabetic subjects with T1-3, N0-3, M0 breast cancer who had completed surgery and (neo)adjuvant chemotherapy (if given) provided fasting plasma samples at random assignment and at six months. Glucose was measured locally; blood was aliquoted, frozen, and stored at -80°C. Paired plasma aliquots were analyzed for insulin, hs-CRP, and leptin. Spearman correlation coefficients were calculated and comparisons analyzed using Wilcoxon signed rank test. All statistical tests were two-sided. RESULTS:Mean age was 52.1±9.5 years in the metformin group and 52.6 ± 9.8 years in the placebo group. Arms were balanced for estrogen/progesterone receptor, BMI, prior (neo)adjuvant chemotherapy, and stage. At six months, decreases in weight and blood variables were statistically significantly greater in the metformin arm (vs placebo) in univariate analyses: weight -3.0%, glucose -3.8%, insulin -11.1%, homeostasis model assessment -17.1%, leptin -20.2%, hs-CRP -6.7%; all P values were less than or equal to .03. There was no statistically significant interaction of change in these variables with baseline BMI or insulin. CONCLUSIONS:Metformin statistically significantly improved weight, insulin, glucose, leptin, and CRP at six months. Effects did not vary by baseline BMI or fasting insulin.
RCT Entities:
BACKGROUND:Metformin may improve metabolic factors (insulin, glucose, leptin, highly sensitive C-reactive protein [hs-CRP]) associated with poor breast cancer outcomes. The NCIC Clinical Trials Group (NCIC CTG) MA.32 investigates effects of metformin vs placebo on invasive disease-free survival and other outcomes in early breast cancer. Maintaining blinding of investigators to outcomes, we conducted a planned, Data Safety Monitoring Committee-approved, analysis of the effect of metformin vs placebo on weight and metabolic factors at six months, including examination of interactions with baseline body mass index (BMI) and insulin, in the first 492 patients with paired blood samples. METHODS: Eligible nondiabetic subjects with T1-3, N0-3, M0 breast cancer who had completed surgery and (neo)adjuvant chemotherapy (if given) provided fasting plasma samples at random assignment and at six months. Glucose was measured locally; blood was aliquoted, frozen, and stored at -80°C. Paired plasma aliquots were analyzed for insulin, hs-CRP, and leptin. Spearman correlation coefficients were calculated and comparisons analyzed using Wilcoxon signed rank test. All statistical tests were two-sided. RESULTS: Mean age was 52.1±9.5 years in the metformin group and 52.6 ± 9.8 years in the placebo group. Arms were balanced for estrogen/progesterone receptor, BMI, prior (neo)adjuvant chemotherapy, and stage. At six months, decreases in weight and blood variables were statistically significantly greater in the metformin arm (vs placebo) in univariate analyses: weight -3.0%, glucose -3.8%, insulin -11.1%, homeostasis model assessment -17.1%, leptin -20.2%, hs-CRP -6.7%; all P values were less than or equal to .03. There was no statistically significant interaction of change in these variables with baseline BMI or insulin. CONCLUSIONS:Metformin statistically significantly improved weight, insulin, glucose, leptin, and CRP at six months. Effects did not vary by baseline BMI or fasting insulin.
Authors: E Bonora; G Targher; M Alberiche; R C Bonadonna; F Saggiani; M B Zenere; T Monauni; M Muggeo Journal: Diabetes Care Date: 2000-01 Impact factor: 19.112
Authors: Pamela J Goodwin; Kathleen I Pritchard; Marguerite Ennis; Mark Clemons; Margaret Graham; I George Fantus Journal: Clin Breast Cancer Date: 2008-12 Impact factor: 3.225
Authors: G Zhou; R Myers; Y Li; Y Chen; X Shen; J Fenyk-Melody; M Wu; J Ventre; T Doebber; N Fujii; N Musi; M F Hirshman; L J Goodyear; D E Moller Journal: J Clin Invest Date: 2001-10 Impact factor: 14.808
Authors: Y Shu; C Brown; R A Castro; R J Shi; E T Lin; R P Owen; S A Sheardown; L Yue; E G Burchard; C M Brett; K M Giacomini Journal: Clin Pharmacol Ther Date: 2007-07-04 Impact factor: 6.875
Authors: Ana Elisa Lohmann; Mira F Liebman; William Brien; Wendy R Parulekar; Karen A Gelmon; Lois E Shepherd; Jennifer A Ligibel; Dawn L Hershman; Priya Rastogi; Ingrid A Mayer; Timothy J Hobday; Julie Lemieux; Alastair Mark Thompson; Kathleen I Pritchard; Timothy Joseph Whelan; Som D Mukherjee; Haji I Chalchal; Vanessa Bernstein; Vuk Stambolic; Bingshu E Chen; Pamela Jean Goodwin Journal: Breast Cancer Res Treat Date: 2017-04-26 Impact factor: 4.872
Authors: Zhongbo Liu; Noriko N Yokoyama; Christopher A Blair; Xuesen Li; Daina Avizonis; Xue-Ru Wu; Edward Uchio; Ramy Youssef; Michael McClelland; Michael Pollak; Xiaolin Zi Journal: Mol Cancer Ther Date: 2016-02-26 Impact factor: 6.261
Authors: Neil M Iyengar; Kristy A Brown; Xi Kathy Zhou; Ayca Gucalp; Kotha Subbaramaiah; Dilip D Giri; Heba Zahid; Priya Bhardwaj; Nils K Wendel; Domenick J Falcone; Hanhan Wang; Samantha Williams; Michael Pollak; Monica Morrow; Clifford A Hudis; Andrew J Dannenberg Journal: Cancer Prev Res (Phila) Date: 2017-03-07
Authors: Kathy Pan; Rebecca A Nelson; Jean Wactawski-Wende; Delphine J Lee; JoAnn E Manson; Aaron K Aragaki; Joanne E Mortimer; Lawrence S Phillips; Thomas Rohan; Gloria Y F Ho; Nazmus Saquib; Aladdin H Shadyab; Rami Nassir; Jinnie J Rhee; Arti Hurria; Rowan T Chlebowski Journal: J Natl Cancer Inst Date: 2020-02-01 Impact factor: 13.506
Authors: Neil M Iyengar; Xi Kathy Zhou; Ayca Gucalp; Patrick G Morris; Louise R Howe; Dilip D Giri; Monica Morrow; Hanhan Wang; Michael Pollak; Lee W Jones; Clifford A Hudis; Andrew J Dannenberg Journal: Clin Cancer Res Date: 2015-12-28 Impact factor: 12.531